Crush resistant formulation of oxymorphone approved in US
17th January 2012
The US Food and Drug Administration (FDA) have approved a crush resistant formulation of oxymorphone which is aimed at reducing abuse potential. The company (Endo Pharmaceuticals, Chadds Ford, Pennsylvannia, USA) plans to retain the name Opana ER and replace the 7 dosage strengths of the current formulation of Opana ER with the new crush resistant product during 2012.
Recent news
- Die zweite Ausgabe des APM Newsletter ist fertig.
- Prescribing and mixing controlled drugs - changes
- Tolvaptan: over-rapid increase in serum sodium and risk of serious neurological events
- Risks of hypomagnesaemia and increased risk of fracture with long-term PPI use
- NICE updated infection control guidelines
- MHRA alert for co-codamol 8/500 tablets
- NPSA RRR: Harm from flushing of nasogastric tubes before confirmation of placement
- Capsaicin patch license extension application withdrawn
- Wir freuen uns, Ihnen den ersten APM Newsletter vorstellen zu dürfen
- Alert update on Prednisolone e/c recalled from Teva
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000